Evidence map›Paper›PMID 36619666›Full record

ArticleJournal of King Saud University. Science2023

Inhibition of SARS-CoV2 viral infection with natural antiviral plants constituents: An in-silico approach.

Kuntal Das, Paramita Das, Mansour Almuqbil, Syed Mohammed Basheeruddin Asdaq, K Nikhil, K Preethi, A Angelinkiruba, Nasser Fawzan Alomar, Rawabi M Al Harbi, Walaa A Al Abdullah and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of King Saud University. Science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Ayurvedic and Chinese Herbs against Coronaviruses.Current pharmaceutical design · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Kuntal DasNITTE College of Pharmacy, Yelahanka, Bangalore 560064, India.
Paramita DasKrupanidhi College of Pharmacy, #12/1, Chikkabelandur, Carmelaram Post, Varthur Hobli, Bangalore 560035, India.
Mansour AlmuqbilDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Syed Mohammed Basheeruddin AsdaqDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, 13713 Riyadh, Saudi Arabia.
K NikhilKrupanidhi College of Pharmacy, #12/1, Chikkabelandur, Carmelaram Post, Varthur Hobli, Bangalore 560035, India.
K PreethiKrupanidhi College of Pharmacy, #12/1, Chikkabelandur, Carmelaram Post, Varthur Hobli, Bangalore 560035, India.
A AngelinkirubaKrupanidhi College of Pharmacy, #12/1, Chikkabelandur, Carmelaram Post, Varthur Hobli, Bangalore 560035, India.
Nasser Fawzan AlomarEquame Scientific and Research Center, Riyadh, Saudi Arabia.
Rawabi M Al HarbiPharmaceutical Services, King Saud Medical City, Riyadh, Saudi Arabia.
Walaa A Al AbdullahPharmaceutical Services, King Saud Medical City, Riyadh, Saudi Arabia.
Sami M AlshehriPharmaceutical Services, King Saud Medical City, Riyadh, Saudi Arabia.
Yahya A LaghabiPharmaceutical Services, King Saud Medical City, Riyadh, Saudi Arabia.
Ahmed R AlsaeghClinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Yahya MohzariClinical Pharmacy Department, King Saud Medical City, Riyadh, Saudi Arabia.
Sultan AlshehriDepartment of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.
Basheerahmed Abdulaziz MannasahebDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, 13713 Riyadh, Saudi Arabia.
Syed Imam RabbaniDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
King Saud Medical City · SAAlmaarefa UniversityAlfaisal University · SAKing Saud University · SANitte University · INQassim University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: In 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) was declared pandemic. Advancement in computational technology has provided rapid and cost-effective techniques to test the efficacy of newer therapeutic agents. This study evaluated some of the potent phytochemicals obtained from AYUSH (Ayurveda, Yoga, Naturopathy, Unani, Siddha, Sowa-Rigpa, and Homeopathy)-listed medicinal plants against SARS-CoV-2 proteins using computational techniques. Materials and methods: The potential SARS-CoV-2 protein targets were utilized to study the ligand-protein binding characteristics. The bioactive agents were obtained from ashwagandha, liquorice, amla, neem, tinospora, pepper, and stevia. Ivermectin was utilized as a reference agent to compare its efficacy with phytochemicals. Results: The computational analysis suggested that all the bioactive components from the selected plants possessed negative docking scores (ranging from -6.24 to -10.53). The phytoconstituents were well absorbed, distributed in the body except for the CNS, metabolized by liver enzymes, well cleared from the body, and well tolerated. The data suggest that AYUSH-recommended plants demonstrated therapeutic efficacy against SARS CoV-2 virus infection with significantly reduced toxicity. Conclusion: The phytoconstituents were found to hinder the early stages of infection, such as absorption and penetration, while ivermectin prevented the passage of genetic material from the cytoplasm to the nucleus. Additional research involving living tissues and clinical trials are suggested to corroborate the computational findings.

Indexed as

AntioxidantCOVID-19Molecular dockingNatural productPharmacokineticsToxicity

Identifiers

PMID36619666
PMCPMC9811905
OpenAlexW4313593872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.